Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Clinical Chemistry Analyzer Provides DAU Screening

By LabMedica International staff writers
Posted on 02 Aug 2017
The expanded capability of a clinical chemistry analyzer has been announced to now provide drugs of abuse urine screening (DAU). More...
No hardware or software updates are required, and the added functionality will benefit both current owners and new customers.

EasyRA clinical chemistry analyzer is a fully automated clinical chemistry analyzer that accommodates the diverse needs of small laboratories. The decision to expand the EasyRA’s capabilities into DAU was driven by the call of laboratory and healthcare professionals for a moderately complex, benchtop clinical chemistry analyzer that can also provide urine drug screening.

The EasyRA clinical chemistry system combines moderately complex drugs of abuse and routine chemistry on a single, easy-to-use, moderately complex benchtop analyzer. The EasyRA will offer a panel of drugs of abuse with simply interpreted positive or negative results, to eliminate the need for subjective interpretation in the moderately complex setting. The reagents to enable the new assays are immediately available from Medica’s distribution partners.

Robert Hagopian, BSc, JD, the President, and CEO, Medica Corporation, sad, “Patients and providers will benefit from accurate and cost-effective results when providing pain management treatment, and for applications requiring drugs of abuse screening. This combination of chemistry and DAU screening ability will uniquely position EasyRA users to provide more, faster, and more cost-effective analysis than before. With this announcement, we are continuing to fulfill our commitment to deliver the latest product updates in one convenient installation.” Medica will debut and demonstrate the EasyRA analyzer’s new capability at the annual scientific meeting of the American Association for Clinical Chemistry (AACC), held August 1-3, 2017, in San Diego, CA, USA.

Related Links:
Medica Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.